Annual Congress Berlin 2001

Saturday, 22.09.2001
Sunday, 23.09.2001
Monday, 24.09.2001
Tuesday, 25.09.2001
Wednesday, 26.09.2001

Citations should be made in the following way: Authors. Title. Eur Respir J 2004; 18: Suppl. 33, abstract number.

Material from 2001:

3025 Abstracts

Material from 2001: Show

Long-acting β2-agonists: clinical effects

Oral Presentation
Chairs: E. Bel (Leiden, The Netherlands), B. O'Connor (London, UK)

Download all media

Rapid onset bronchodilation with formoterol or salbutamol in patients with chronic obstructive pulmonary disease (COPD) D. Benhamou, J. F. Muir, V. Leclerc, V. Le Gros, I. Bourdeix (Rouen, Paris, Rueil-Malmaison, France)
Acute effects of higher than customary doses of salmeterol (SM) and salbutamol (SB) in patients with acute exacerbation of COPD M. Cazzola, F. Calderaro, F. Di Perna, C. Califano, M. D'Amato, M. G. Matera, G. D'Amato (Naples, Italy)
Will a cumulative dose reversibility test increase the power in a dose-response study comparing formoterol and terbutaline? P. Arvidsson, P. Jemsby, J. Ziegler, E. Millinger, M. Perpiña, H. Verea, P. Larsson, Y. Gnosspelius (Gothenburg, Varberg, Eksjo, Linkoping, Lund, Sweden; Valencia, La Coruna, Spain)
Bronchodilatory effects of formoterol in patients with chronic obstructive pulmonary disease (COPD) are not influenced by concomitant corticosteroid use P. Kristufek, B. Levine, G. Della Cioppa, A. Byrne, D. Till (Bratislava, Slovakia; Phoenix, United States Of America; Horsham, United Kingdom)
The efficacy of formoterol in patients with chronic obstructive pulmonary disease (COPD) is not influenced by concomitant corticosteroid use A. P. M. Greefhorst, M. H. Thomson, A. Byrne, D. Till (Hengelo, The Netherlands; Horsham, United Kingdom)
The influence of polymorphisms of the β₂- adrenoceptor (AR) gene and the β₂-AR upstream peptide (BUP) on bronchoprotective tolerance development in asthmatic patients A. van Veen, E. A. Wierenga, F. R. Weller, H. M. Jansen, R. E. Jonkers (Amsterdam, The Netherlands)
Formoterol protects against platelet-activating factor-induced lung function abnormalities in asthma J. Gabrijelcic, A. Casas, R. Rabinovich, A. Acuña, J. A. Barbera, J. Roca, K. F. Chung, R. Rodriguez-Roisin (Barcelona, Spain; London, United Kingdom)
Appropriateness of prescribing practices of long- acting B₂ agonists in COPD in two large district general hospitals M. Al-Aloul, M. J. Walshaw, M. J. Ledson (Liverpool, United Kingdom)